21 results
8-K
EX-99.5
KANT
Kineta, Inc.
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
utilizes third parties to, among other things, manufacture raw materials and Kineta’s product candidates, components, parts and consumables … affect the availability or cost of goods and services, including raw materials and other natural resources, necessary to run Kineta’s business
424B3
KANT
Kineta, Inc.
10 Nov 22
Prospectus supplement
4:21pm
.
Kineta currently utilizes third parties to, among other things, manufacture raw materials and Kineta’s product candidates, components, parts
425
4xqtfms179i7urc
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.1
n7owm
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-10.1
rfvk77l
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
424B3
bt7n7
12 Nov 20
Prospectus supplement
6:08am
S-4
wkgbhlcwlvfv57
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm
8-K
EX-2.1
xdhlo
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
8-K
EX-2.2
tbch vcwsvt
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
425
EX-2.1
h6biagtkfurz5
24 Aug 20
Business combination disclosure
5:28pm